News

Some thoughts around the industry continuing to grapple with the high price tag associated with drug development costs.

Outlining the nation’s key changes and current requirements in processing investigational and new drug applications.

Why and how FDA is funding a digital biomarkers study that centers on quality of life for patients with heart failure.

A view of the notable policy strategies advanced in 2019 to boost drug development and review.

Peter O’Donnell explores where the EU stands today in R&D pursuits for new antibacterial therapies.

The regulatory path for virtual studies is nebulous and potentially difficult to navigate-finding a way forward requires a thorough understanding of the terrain and how to apply existing legal frameworks.

Higher screen failure and patient dropout rates are raising the imperative to pilot and implement new study conduct models in trial recruitment and retention.

Pharmaceutical companies should consider implementing a structured, semi-automated process for intake of compassionate use requests. says ViiV Healthcare executives.

While the future of the industry is still uncertain, a slew of uplifting ideas around innovation could help turn things around.

All of the latest happenings in the industry, all in one place.